Articulation disorders and duration, severity and L-dopa dosage in idiopathic parkinson’s disease

Neurologia i Neurochirurgia Polska

Volumn 49, Issue 5, 2015, Pages 302-306

  Pawlukowska, Wioletta ^a   Gołąb Janowska, Monika ^a   Safranow, Krzysztof ^a   Rotter, Iwona ^a   Amernik, Katarzyna ^a   Honczarenko, Krystyna ^a   Nowacki, Przemysław ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Dysarthria; Parkinson disease; Speech disturbances; Speech therapy

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; HOEHN AND YAHR SCALE; HUMAN; LIP MALFORMATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; SPEECH AND LANGUAGE ASSESSMENT; SPEECH SOUND DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE; VOICE ANALYSIS; ARTICULATION DISORDERS; BREATHING; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; JAW; JOINT CHARACTERISTICS AND FUNCTIONS; LIP; MIDDLE AGED; PATHOLOGICAL REFLEX; PATHOPHYSIOLOGY; PHONATION; PHONETICS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ARTICULATION DISORDERS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAW; LEVODOPA; LIP; MALE; MIDDLE AGED; PARKINSON DISEASE; PHONATION; PHONETICS; RANGE OF MOTION, ARTICULAR; REFLEX, ABNORMAL; RESPIRATION; SEVERITY OF ILLNESS INDEX;

EID: 84952311899     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/j.pjnns.2015.07.002     Document Type: Article

References (38)

1. Logemann JA, Fisher HB, Boshes B, Blonsky E. Frequency and co occurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J Speech Hear Dis 1978;43:47-57.
2. Ho K, Bradshaw JL, Iansek R. For better or worse: the effect of Levodopa on speech in Parkinson's disease. Mov Disord 2008;23:574-80.
3. Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson's disease. Expert Rev Neurother 2008;8(2):299-311.
4. Yorkston KM, Miller RM, Strand EA. Management of speech and swallowing in degenerative diseases. Austin, Texas: Pro-Ed; 2004.
5. Rusz J, Cmejla R, Ruzickova H, Ruzicka E. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease. J Acoust Soc Am 2011;129:350-67.
6. Skodda S, Schlegel U. Speech rate and rhythm in Parkinson's disease. Mov Disord 2008;23:985-92.
7. Logemann J, Boshes B, Fisher H. The steps in the degeneration of speech and voice control in Parkinson's disease. In: Siegfried J, editor. Parkinson's disease: rigidity, akinesia, behavior. Vienna: Hans Huber; 1973.
8. Logemann JA. Evaluation and treatment of swallowing disorders. Austin, Texas: Pro-Ed; 1998.
9. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-54.
10. Wolfe V, Garvin JS, Bacon M, Waldrop W. Speech changes in Parkinson's disease during treatment with L-dopa. J Commun Disord 1975;8:271-9.
11. Solomon NP, Hixon TJ. Speech breathing in Parkinson's disease. J Speech Hear Res 1993;36:294-310.
12. Leanderson R, Meyerson BA, Persson A. Effect of L-dopa on speech in parkinsonism: an EMG study of lacbial articulatory function. J Neurol Neurosurg Psychiatry 1971;34:679-81.
13. Nakano KK, Zubicki H, Tyler HR. Speech defects of parkinsonian patients: effects of levodopa therapy on speech intelligibility. Neurology 1973;23:865-70.
14. Rigrodsky S, Morrison EB. Speech change in Parkinsonism during L-dopa therapy: preminary findings. J Am Geriatr Sci 1970;18:142-51.
15. Skodda S, Grönheit W, Schlegel U. Impairment of vowel articulation as a possible marker of disease progression in Parkinson's disease. PLOS ONE 2012;7(2):e32132.
16. Cahill ML, Murdoch EB, Theodoros GD, Triggs JE, Charles GB, et al. Effect of oral levodopa treatment on articulatory function in Parkinson's disease: preliminary results. Motor Control 1998;2:161-72.
17. De Letter M, Santens P, De Bodt M, Van Maele G, Van Borsel J, et al. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clin Neurol Neurosurg 2007; 109:495-500.
18. Goberman A, Blomgren M. Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations. J Fluency Disord 2003;28:55-70.
19. Ho A, Bradshaw JL, Iansek R. For better or for worse: the effect of levodopa on speech in Parkinson's disease. Mov Disord 2008;23(4):574-80.
20. Perez KS, Ramig LO, Smith ME, Dromey C. The Parkinson larynx: tremor and videostroboscopic findings. J Voice 1996;10:354-61.
21. Liotti M, Ramig LO, Vogel D, et al. Hypophonia in Parkinson's disease: neural correlates of voice treatment revealed by PET. Neurology 2003;60:432-40.
22. Pinto S, Thobois S, Costes N, Le Bars D, Benabid AL, et al. Subthalamic nucleus stimulation and dysarthria in Parkinson's disease: a PET study. Brain 2004;127:602-15.
23. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recomendations. Mov Disord 2003;18:738-50.
24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
25. Enderby P, Palmer R. Frenchay Dysarthria Assessment. English; 1983.
26. Shapiro SS, Wilk MB. An analysis of variance test for nomality (complete samples). Biometics 1965;52:591-611.
27. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
28. Stanisz A. Przystępny kurs statystyki z zastosowaniem Statistica PL na przykładach z medycyny, tom I-III. Kraków: StatSoft; 2007.
29. Krysicki W, Bartos J, Dyczka W, Królikowska K, Wasilewski M. Rachunek prawdopodobieństwa i statystyka matematyczna w zadaniach, część 2. Statystyka matematyczna. Warszawa: PWN; 2006. p. 230-1.
30. Ackermann H, Hertrich I, Hehr T. Oral diadochokinesis in neurological dysarthrias. Folia Phoniatr Logop 1995;47:15-23.
31. Canter G. Speech characteristics of patients with Parkinson's disease. II. Physiological supporte for speech. J Speech Hear Dis 1965;30:44-9.
32. Ramig LO, Countryman S, O'Brien C, Pawlas AA, O'Brei C, Hoehn MM, et al. Intensive speech treatment for people with Parkinson's disease: short and long term comparison of two techniques. Neurology 1996;47:1496-504.
33. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-7.
34. Forrest K, Weismer G, Turner GS. Kinematic, acoustic, and perceptual analysis of connected speech produced by parkinsonian and normal geriatric adults. J Acou Soc Am 1989;85:2608-22.
35. Dromey C. Spectral measures and perceptual ratings of hypokinetic dysarthria. J Med Speech Lang Pathol 2003;11:85-94.
36. Skodda S, Rinsche H, Schlegel U. Progression of dysprosody in Parkinson's disease over time-a longitudinal study. Mov Disord 2009;24:716-22.
37. Holmes RJ, Oates JM, Phyland DJ, Hughes AJ. Voice characteristics in the progression of Parkinson's disease. Int J Lang Commun Disord 2000;35:407-18.
38. Tykalova T, Rusz J, Cmejla R, Klempir J, et al. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study. J Neural Transm 2015.